Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 43, Issue 5, 2016, Pages 898-905

  Sahlmann, Carsten Oliver ^a   Meller, Birgit ^a   Bouter, Caroline ^a   Ritter, Christian Oliver ^a   Ströbel, Philipp ^a   Lotz, Joachim ^a   Trojan, Lutz ^a   Meller, Johannes ^a   Hijazi, Sameh ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

68Ga; HBED; PET; PET CT; Prostate carcinoma; PSMA

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; RADIOISOTOPE; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; PET-CT SCANNER; PREDICTIVE VALUE; PRIMARY TUMOR; PROSTATE CARCINOMA; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; CARCINOMA; DIAGNOSTIC IMAGING; EVALUATION STUDY; MALE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSTATE TUMOR; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOMETALLIC COMPOUNDS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84946854809     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3251-y     Document Type: Article

References (23)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.
2. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003;170:1872–6.
3. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. doi:10.1007/s00259-013-2525-5.
4. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42(9):1412–7.
5. Alkhawaldeh K, Bural G, Kumar R, Alavi A. Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2008;35(2):246–52.
6. Sahlmann CO, Siefker U, Lehmann K, Meller J. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun. 2004;25(8):819–23.
7. Schottelius M, Šimeček J, Hoffmann F, Willibald M, Schwaiger M, Wester HJ. Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE. EJNMMI Res. 2015;5:22.
8. Meller B, Meller J, Sahlmann CO, Hijazi S, Trojan L, Thelen P. V52 Medikamentöse Beeinflussung der Aufnahme von F-18-Flormethylcholin (FMC) und Ga-68-PSMAHEBD sowie der prostataspezifischen Membranantigen (PSMA)-mRNAExpression in In-vitro-Modellen des Prostatakarzinoms (PC). Nuklearmedizin. 2014;53(1):A2–109.
9. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell. 2003;14(12):4835–45.
10. Martin R, Juttler S, Muller M, Wester HJ. Cationic eluate pretreatment for automated synthesis of [(6)(8)Ga]CPCR4.2. Nucl Med Biol. 2014;41:84–9.
11. Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.
12. Bouchelouche K, Choyke PL, Capala J. Prostate specific membrane antigen a target for imaging and therapy with radionuclides. Discov Med. 2010;9:55–61.
13. 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015;56(5):668–74.
14. Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by (68) Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015. doi:10.1002/pros.23091.
15. Eder M, Neels O, Muller M, Bauder-Wust U, Remde Y, Schafer M, et al. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals. 2014;7:779–96.
16. Conti M. New prospects for PET in prostate cancer imaging: a physicist's viewpoint. EJNMMI Physics. 2014;1:11.
17. Kadrmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW. Impact of time-of-flight on PET tumor detection. J Nucl Med. 2009;50:1315–23.
18. Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42(2):210–4.
19. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.
20. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA targeted theranostic concept and first proof of concept human studies. J Nucl Med. 2015;56(8):1169–76.
21. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–95. doi:10.1007/s00259-012-2298-2.
22. Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer. Theranostics. 2012;2(3):318–30. doi:10.7150/thno.4008.
23. Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, et al. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015;17(4):575–84.